- A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumorsLi, Huiping; Huang, Yan; Zhang, Li; Chen, Zhendong; Zeng, Aiping; Zhang, Helong; Yu, Yan; Wei, Shihong; Li, Qingshan; Wang, Xiaojia; Wang, Xiangcai; Wang, Xiuwen; Yang, Runxiang; Dai, Xiumei; Bi, Minghong; Sun, Tao; Zhang, Qingyuan; Han, Cuicui; Liu, Qianqian; Li, YujieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 studyZhao, Mingchuan; Hu, Xichun; Zeng, Aiping; Yu, Yan; Shi, Huaqiu; Chen, Zhendong; Sun, Hongmei; Yang, Weihua; Sheng, Lili; Peng, Peijian; Wang, Jingfen; Yi, Tienan; Bi, Minghong; Ni, Mingli; Dai, Xiumei; Hu, Changlu; Lei, Kaijian; Yuan, Xia; Li, Qingshan; Lv, DongqingAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- A Double-blind Phase III Trial of Denosumab Biosimilar QL1206 vs Denosumab in Bone Metastatic Tumor: Lung Cancer Cohort DataHuang, Y.; Zeng, A.; Zhang, H.; Yu, Y.; Yang, R.; Chen, Z.; Zhang, Y.; Wei, S.; Bi, M.; Wang, X.; Han, C.; Liu, Q.; Li, Y.; Zhang, L.
会议论文
Efficacy and safety of the biosimilar QL1206 compared with denosumab in breast cancer with bone metastases: subgroup analyses of a phase III study
8阅读
